液相芯片技术一步反应法联合定量测定人血清CEA、AFP及tPSA.docVIP

液相芯片技术一步反应法联合定量测定人血清CEA、AFP及tPSA 　【摘要】 目的 建立用液相芯片技术同时定量测定人血清中癌胚抗原（CEA）、甲胎蛋白（AFP）和总前列腺特异性抗原（tPSA）水平的一步反应法，并对该方法进行评价。方法 制备抗体交联微球及生物素标记抗体，用双抗体夹心法测定临床血清标本。结果 联合测定CEA、AFP和tPSA的线性范围分别为0.063～200 ng/ml、0.052～66.6 ng/ml、0.016～20 ng/ml； 最低检测限分别为31.3 pg/ml、26.0 pg/ml、7.8 pg/ml； 批内精密度lt;10 %，批间精密度lt;14 %； 血清标本CEA、AFP和tPSA检测值与化学发光免疫分析法（CLIA）测值的相关系数为0.920～0.940，与液相芯片两步反应法测值的相关系数为0.952～0.979。该方法仅需1 μl标本，2 h即可完成检测。结论 液相芯片一步反应法具有高通量、检测范围广、灵敏度高、重复性好、节省样品和时间等优点，具有较大临床应用潜力。 【关键词】 液相芯片； Luminex； 肿瘤标志物 【Abstract】 Objective To establish a onestep assay to simultaneously quantify carcinoembryonic antigen (CEA),alpha fetoprotein (AFP) and total prostate specific antigen (tPSA) in human serum using multiplexed Luminex assay and evaluate its assay performance.Methods Antibodyconjugated microspheres and biotinylated detection antibodies were prepared.A sandwich immunoassay was established to measure the levels of CEA,AFP and tPSA in clinical serum samples.Results The linear range for the measurement of CEA,AFP and tPSA was 0.063～200 ng/ml,0.052～66.6 ng/ml,0.016～20 ng/ml,respectively.The lower detection limit of CEA,AFP and tPSA was 31.3 pg/ml,26.0 pg/ml,7.8 pg/ml,respectively.The intra and interassay coefficients of variation were less than 9 % and 14%.The correlation coefficients (r) of measurement of CEA,AFP and tPSA were 0.920～0.940 compared with chemiluminescence immunoassay (CLIA),and 0.952～0.979 compared with the twostep Luminex assay.In addition,only 1 microliter of serum and 2 hours were required for the assay.Conclusion With the advantages of unique capability of multiplexing and highthroughput,good reproducibility,increased detection range and sensitivity,the onestep Luminex assay would have great potential in future clinical application. 【Key words】 suspension bead array； Luminex； tumor markers 肿瘤标志物在肿瘤的临床诊断和治疗中占有重要地位。由于数种肿瘤标志物联合检测对肿瘤的早期诊断及疗效监测更具价值，而同时检测多项指标依靠传统检测手段无法实现，因此在实际工作中亟需一种能够同时完成多指标检测的新型试剂。液相芯片是一种新型生物芯片技术平台，它在不同荧光编码的微球上进行抗原抗体及核酸杂交反应，通过两束激光分别检测微球编码和荧光信号以达到定性和定量分析